Drugmakers Plot Way into Obesity Market with Deals and Development

Pharmaceutical executives from Amgen (AMGN.O) to Pfizer (PFE.N) are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk’s (NOVOb.CO) Wegovy and Zepbound from Eli Lilly (LLY.N). At stake is a market that is now estimated to reach $100 billion at a minimum by the end of the decade, as consumers flock to the new treatments that have been shown to reduce weight by as much as 20%. Drugmakers are testing these drugs for other health benefits such as lowering cardiovascular disease risk and obstructive sleep apnea.

Read the full article: Drugmakers Plot Way into Obesity Market with Deals and Development //

Source: https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-plot-way-into-obesity-market-with-deals-development-2024-01-11

Scroll to Top